Dr. Armitage has disclosed that he receives consulting fees from ZIOPHARM Oncology, Inc.; GlaxoSmithKline; Spectrum Pharmaceuticals; and Roche; and serves on the board of directors for TESARO Bio, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network
Ms. Green has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education & Grants
Ms. Moonan has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education & Grants
Ms. Gianola has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations
Ms. Gregory has disclosed that she has no relevant financial relationships.
Soupir CP, Vergilio JA, Dal Cin P et al.. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007;127:642–650.
Paietta E, Racevskis J, Bennett JM et al.. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience. Leukemia 1998;12:1881–1885.
Cuneo A, Ferrant A, Michaux JL et al.. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996;81:423–427.
Konoplev S, Yin CC, Kornblau SM et al.. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 2013;54:138–144.
Frankfurt O, Platanias LC. Philadelphia chromosome positive acute myeloid leukemia or de novo chronic myeloid leukemia-blast phase? Leuk Lymphoma 2013;54:1–2.
Cho BS, Kim HJ, Lee S et al.. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. Eur J Haematol 2007;79:170–173.
Bene MC, Castoldi G, Knapp W et al.. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783–1786.
Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, Johansson B. Chemotherapy-related - late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997;11:1571–1574.
Bacher U, Haferlach T, Alpermann T et al.. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol 2011;152:713–720.
Chen Z, Morgan R, Notohamiprodjo M et al.. The Philadelphia chromosome as a secondary change in leukemia: three case reports and an overview of the literature. Cancer Genet Cytogenet 1998;101:148–151.
Ueda K, Horiike S, Zen K et al.. Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia. Leuk Lymphoma 2006;47:1967–1969.
Yip SF, Wan TS, Liu HS et al.. Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment. Leukemia 2006;20:2050–2051.
Drummond MW, Lush CJ, Vickers MA et al.. Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia 2003;17:463–465.
Jentsch-Ullrich K, Pelz AF, Braun H et al.. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica 2004;89:ECR15.
Lazarevic V, Golovleva I, Nygren I, Wahlin A. Induction chemotherapy and post-remission imatinib therapy for de novo BCR-ABL-positive AML. Am J Hematol 2006;81:470–471.
Kondo T, Tasaka T, Sano F et al.. Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. Leuk Res 2009;33:e137–138.
Maddox AM, Keating MJ, Trujillo J et al.. Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapy. Leuk Res 1983;7:509–522.
Miura I, Takatsu H, Yamaguchi A et al.. Standard Ph chromosome, t(9;22)(q34;q11), as an additional change in a patient with acute myelomonocytic leukemia (M4Eo) associated with inv(16) (p13q22). Am J Hematol 1994;45:94–96.
Mozziconacci MJ, Sainty D, Gabert J et al.. The Philadelphia chromosome as a secondary abnormality in two cases of acute myeloid leukemia. Br J Haematol 1998;102:873–875.
Secker-Walker LM, Morgan GJ, Min T et al.. Inversion of chromosome 16 with the Philadelphia chromosome in acute myelomonocytic leukemia with eosinophilia. Report of two cases. Cancer Genet Cytogenet 1992;58:29–34.
O'Donnell MR, Tallman MS, Abboud CN et al.. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 2.2014. Available at: NCCN.org. Accessed May 21, 2014.
O'Brien S, Radich JP, Abboud CN et al.. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 3.2014. Available at: NCCN.org. Accessed May 21, 2014.